GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

SK Bioscience Co 302440.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

40,400

+5.21%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩651.37bn

FY2018FY2025

Net income

−₩57.42bn

FY2018FY2025

Free cash flow

−₩157.87bn

FY2018FY2025

Shareholders' equity

₩1.79trn

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue₩651.37bn₩267.55bn₩369.51bn₩456.73bn₩929.00bn₩225.61bn₩183.94bn₩88.17bn
Gross profit₩166.94bn₩30.98bn₩142.24bn₩239.61bn₩570.28bn₩95.34bn₩79.64bn₩39.22bn
Research and development₩69.86bn₩71.35bn₩85.74bn₩57.96bn₩47.25bn₩25.99bn₩27.72bn₩10.51bn
Operating income−₩123.50bn−₩138.43bn−₩11.99bn₩115.01bn₩474.22bn₩37.71bn₩6.47bn₩3.28bn
Net income−₩57.42bn−₩53.88bn₩22.32bn₩122.45bn₩355.14bn₩32.89bn₩14.68bn₩420.8m
Diluted earnings per share-732.13-701.32290.491,594.764,642.34537.41239.836.88

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets₩2.96trn₩2.84trn₩1.85trn₩2.14trn₩2.11trn₩562.23bn₩403.98bn₩402.71bn
Total liabilities₩918.29bn₩821.14bn₩148.58bn₩400.23bn₩508.81bn₩298.44bn₩171.25bn₩191.98bn
Debt₩464.74bn₩383.33bn——₩35.50bn₩102.23bn₩116.63bn₩125.81bn
Shareholders' equity₩1.79trn₩1.80trn₩1.70trn₩1.74trn₩1.60trn₩263.79bn₩232.73bn₩210.73bn
Shares outstanding78m77m77m77m77m61m61m61m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations₩102.51bn−₩128.02bn₩29.35bn−₩124.96bn₩536.59bn₩120.22bn₩21.82bn₩14.90bn
Capital spending−₩260.38bn−₩172.22bn−₩50.30bn−₩76.49bn−₩42.91bn−₩9.93bn−₩23.97bn−₩6.31bn
Free cash flow−₩157.87bn−₩300.24bn−₩20.95bn−₩201.45bn₩493.69bn₩110.30bn−₩2.15bn₩8.59bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩155.71bn₩168.61bn₩184.19bn₩150.76bn₩161.86bn₩154.56bn₩156.85bn₩61.65bn
Gross profit₩41.52bn₩40.29bn₩30.67bn₩32.93bn₩33.42bn₩26.13bn₩5.62bn₩1.83bn
Operating income−₩15.27bn−₩44.54bn−₩51.61bn−₩19.37bn−₩37.40bn−₩15.13bn−₩50.78bn−₩39.61bn
Net income−₩17.89bn−₩33.33bn−₩57.96bn₩24.48bn−₩16.48bn−₩7.47bn−₩6.44bn−₩22.32bn
Diluted earnings per share-228.00-424.79-738.98312.35-210.23-95.29-82.16-290.48
Cash from operations₩2.68bn−₩42.53bn₩23.66bn₩20.65bn−₩4.55bn₩62.74bn−₩12.95bn−₩43.49bn
Capital spending−₩66.94bn−₩67.26bn−₩58.44bn−₩70.94bn−₩81.53bn−₩49.47bn−₩47.96bn−₩38.68bn
Free cash flow−₩64.26bn−₩109.80bn−₩34.77bn−₩50.29bn−₩86.08bn₩13.28bn−₩60.91bn−₩82.17bn
Total assets₩2.98trn₩2.99trn₩2.96trn₩2.92trn₩2.85trn₩2.90trn₩2.84trn₩2.05trn
Debt₩527.75bn₩534.21bn₩464.74bn₩406.45bn₩395.94bn₩395.11bn₩383.33bn₩188.21bn
Shareholders' equity₩1.75trn₩1.77trn₩1.79trn₩1.83trn₩1.79trn₩1.81trn₩1.80trn₩1.72trn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue12.2%23.7%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin21.5%33.2%42.9%—
Operating margin-28.5%-9.1%12.2%—
Net margin-12.1%1.9%14.5%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-65.8-71.9247.946.148.5
Price to sales5.914.715.012.418.6

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.